Frontiers of Medicine
2024,
Volume 18,
Issue 1,
Pages 169-179
doi:10.1007/s11684-023-1011-0
Abstract:
We aimed to investigate the safety and efficacy of nirmatrelvir/ritonavir (Paxlovid) therapy for hemodialysis-dependentThe treatment group included six patients who received 150 mg/100 mg of Paxlovid orally once daily forPaxlovid therapy tended toward early viral clearance and low viral load on Day 8.In the Paxlovid treatment group, we found significantly increased levels of lymphocytes (P=0.03Paxlovid therapy showed a potential therapeutic effect with good tolerance in hemodialysis patients.